JMP maintains $20 target on ProAssurance stock post-earnings

Published 25/02/2025, 11:06
JMP maintains $20 target on ProAssurance stock post-earnings

On Tuesday, JMP Securities analyst Matthew Carletti maintained a Market Outperform rating on ProAssurance Corporation (NYSE:PRA) with a steady price target of $20.00. The insurance provider, currently trading at $14.11, appears fairly valued according to InvestingPro analysis, with a market capitalization of $720 million and a P/E ratio of 17x. Carletti highlighted the company’s fourth-quarter 2024 performance, noting that ProAssurance’s operating earnings per share (EPS) of $0.36 surpassed both JMP’s estimate of $0.25 and the consensus estimate of $0.17. This strong performance aligns with InvestingPro data showing two analysts revising their earnings upward for the upcoming period. For deeper insights into ProAssurance’s financial health and growth prospects, including exclusive analyst forecasts and valuation models, investors can access the comprehensive Pro Research Report on InvestingPro.

The better-than-expected results were largely attributed to higher favorable prior period development (PPD (NASDAQ:PPD)) and stronger limited partnership investments. Specifically, the Specialty Property and Casualty (P&C) segment reported $11.3 million in favorable PPD, exceeding the estimated $4.4 million, and limited partnership investments contributed $5.8 million, significantly above the $1.5 million estimate.

The analyst also pointed out that ProAssurance’s higher expense ratio of 34% was due to increased compensation costs and adjustments to prior period segregated portfolio cell ceding commissions. This was a notable increase from the estimated 29%.

In terms of specific segments, the core Specialty P&C segment, which focuses on medical malpractice (med mal), reported an accident-year loss ratio consistent with estimates at 83%. This figure reflects a continued cautious stance on loss severity trends, particularly in select jurisdictions. The Workers’ Compensation segment also met expectations with a 77% loss ratio, which included ongoing elevated medical loss trends.

Carletti noted that gross written premiums (GWP) in the core Specialty P&C segment remained flat, aligning with estimates. This stability was attributed to cautious underwriting amid competitive market conditions, alongside solid renewal pricing, which saw an 8% increase, and a retention rate of 84%. Meanwhile, the Workers’ Compensation segment experienced a 6% rise in GWP, primarily due to higher audit premiums, though this was partially offset by a decrease in new business from $5.0 million a year ago to $3.0 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.